Free Webinar · July 17 12pm PT · Reserve your spot →
Bipolar disorder is considered treatment-resistant when episodes (depressive, manic, mixed, or rapid-cycling) continue despite adequate trials of mood stabilizers — lithium, valproate, lamotrigine — often combined with antipsychotics. Roughly one-third of bipolar patients meet criteria for treatment resistance [1]. Standard escalation involves polypharmacy, ECT for severe depression, and increasingly, structured ketogenic dietary intervention being studied for mitochondrial mechanisms.
Bipolar disorder is increasingly understood as a disorder of cellular energy metabolism. Mitochondrial dysfunction, chronic neuroinflammation, oxidative stress, and circadian rhythm disruption all show consistent patterns in bipolar populations. Mood stabilizers like lithium work in part on these very systems — GSK-3β inhibition, BDNF upregulation, neuroprotection — but they don’t address the broader metabolic and inflammatory terrain that may be sustaining cycling [2].
The biology most strongly implicated in treatment-resistant bipolar:
A growing body of research positions bipolar as substantially a mitochondrial disorder. The ketogenic diet has shown remarkable preliminary results for mood stabilization in this population, with the mechanism appearing to be metabolic rather than primarily neurochemical [3].
CRP, IL-6, and TNF-α elevations are common in bipolar — particularly during mood episodes. Anti-inflammatory interventions including N-acetylcysteine, omega-3 EPA, and curcumin all have evidence for adjunctive use.
Bipolar is exquisitely sensitive to sleep-wake disruption. Light exposure, melatonin patterns, and rigorous sleep architecture support are all mechanism-targeted.
Lithium itself affects thyroid function; subclinical hypothyroidism worsens depression severity. Full thyroid panels — including reverse T3, antibodies — matter especially here.
Microbiome alterations correlate with mood episode severity and frequency.
Both over- and undermethylation patterns have been described in bipolar; they require opposite supplement approaches.
Lithium, valproate, and antipsychotics all deplete specific nutrients. Carnitine, CoQ10, B vitamins, and magnesium repletion may matter especially.
Glutathione system depletion is common; NAC supports glutathione production.
For bipolar, our blood panel reveals thyroid, metabolic, inflammation, and nutrient markers. NutrEval shows mitochondrial function via organic acids — particularly important here. DUTCH maps the HPA axis. 3×4 Genetics reveals methylation patterns relevant to neurotransmitter metabolism. GI Effects shows microbiome composition and gut inflammation. KBMO FIT 176 with Gut Barrier Panel maps food sensitivities and gut barrier integrity. Environmental toxicant patterns are not uncommon.
A safety note we take seriously: lithium toxicity risk requires renal function monitoring (built into our standard panel), and many supplement choices in bipolar require coordination with the prescribing psychiatrist due to destabilization risk.
If you have existing labs — especially thyroid, lithium levels, and metabolic panels — integrate them.
Phase one focuses on foundational stability — sleep, circadian rhythm, blood sugar, gut barrier, and the most actionable nutrient deficiencies. We do not introduce mood-active interventions casually; everything is sequenced with respect for destabilization risk. Where ketogenic dietary intervention is appropriate, it’s introduced with structure and monitoring. Anti-inflammatory protocols (omega-3 EPA at therapeutic doses, NAC, curcumin) are layered in based on what your testing shows. All choices are coordinated with your prescribing psychiatrist.
For patients on lithium, we maintain the renal monitoring built into our standard panel. You’re not stopping medications. You’re potentiating them by addressing the metabolic terrain.
Program structure: main services page
This works for people with bipolar disorder who are on stable medication management with a qualified psychiatrist, who have residual cycling or symptoms despite that management, and who are ready for the rigor a structured, multi-phase roadmap requires. We do not treat bipolar disorder primarily — we work alongside the psychiatric care that is essential to this condition.